PDS Biotechnology Corporation (PDSB): Price and Financial Metrics
GET POWR RATINGS... FREE!
PDSB Stock Price Chart Interactive Chart >
PDSB Price/Volume Stats
| Current price | $5.38 | 52-week high | $17.85 |
| Prev. close | $4.99 | 52-week low | $3.47 |
| Day low | $4.85 | Volume | 1,234,100 |
| Day high | $5.57 | Avg. volume | 330,498 |
| 50-day MA | $5.55 | Dividend yield | N/A |
| 200-day MA | $8.85 | Market Cap | 153.07M |
PDS Biotechnology Corporation (PDSB) Company Bio
PDS Biotechnology Corporation, a clinical-stage immuno-oncology company pioneering the development of novel multifunctional immunotherapeutic products, today announced the closing of its merger with Edge Therapeutics, Inc. Following the merger, Edge will operate as “PDS Biotechnology Corporation” and the stock will trade on the Nasdaq Capital Market beginning on March 18, 2019 under the ticker symbol \
Latest PDSB News From Around the Web
Below are the latest news stories about PDS Biotechnology Corp that investors may wish to consider to help them evaluate PDSB as an investment opportunity.
PDS Biotech posts early safety data for PDS0101, Keytruda combo in head and neck cancerAfter four straight sessions of declines, the shares of PDS Biotechnology (PDSB +3.0%) are trading higher on Thursday after the clinical-stage biotech company reported initial safety data for an experimental drug combination from a mid-stage study in head and neck cancer. The Phase 2 VERSATILE-002 trial was designed to assess... |
PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers SymposiumPreliminary safety data has shown that PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer is likely safe and well tolerated without evidence of enhanced or significant toxicity FLORHAM PARK, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based o |
PDS Biotechnology: Versamune Platform Targeting HPV-Associated CancersPDS Biotechnology (PDSB) is based in New Jersey. For this post, I will focus on the Versamune platform of the company in oncology. PDS Biotechnology's Versamune platform leverages the body's own defense systems to prime antigen-specific CD8+ killer T cells and memory T cells. The company is combining its proprietary... |
H.C. Wainwright Sticks to Its Buy Rating for PDS Biotechnology (PDSB)H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on PDS Biotechnology (PDSB – Research Report) today and set a price target of $15.00. The company's shares closed last Tuesday at $6.96. According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -17.4% and a 24.3% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. PDS Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $15.00, representing an 113.7% upside. |
PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Head and Neck CancerThe study evaluates PDS0101 with and without KEYTRUDA® prior to surgery for HPV-associated oropharyngeal cancer FLORHAM PARK, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced the initiation of an Investigator-Initiated Trial (ITT), MC200710, for P |
PDSB Price Returns
| 1-mo | -0.74% |
| 3-mo | -10.48% |
| 6-mo | -43.07% |
| 1-year | -55.90% |
| 3-year | -22.03% |
| 5-year | -97.24% |
| YTD | -33.58% |
| 2021 | 278.50% |
| 2020 | -19.25% |
| 2019 | -58.72% |
| 2018 | -96.57% |
| 2017 | -25.04% |
Loading social stream, please wait...